TABLE 1.
Phenotypic profiles and corresponding fT>MIC of tested S. aureus isolates in standard- and high-inoculum studiesa
| S. aureus isolate | Isolate no. from referenced in vitro data (reference) | Phenotypeb | Ceftaroline MIC (mg/liter) | fT>MIC (%) |
|---|---|---|---|---|
| 477 | 89608 (13) | MSSA | 0.13 | 100 |
| 478 | 89637 (13) | MSSA | 0.13 | 100 |
| 479 | 83771 (13) | CA-MRSA | 0.5 | 81.7 |
| 480 | 84495 (13) | HA-MRSA | 0.5 | 81.7 |
| 456 | VRS3a (13) | VRSA | 0.5 | 81.7 |
| 435 | NRS4 (13) | VISA | 1 | 60.8 |
| 412c | 412 (14) | MRSA | 1 | 60.8 |
| 449c | 449 (14) | hVISA | 1 | 60.8 |
| 454c | 454 (14) | VISA | 1 | 60.8 |
a
fT>MIC data from reference 10.
b
CA, community acquired; HA, health care acquired; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; VISA, vancomycin-intermediate Staphylococcus aureus; VRSA, vancomycin-resistant Staphylococcus aureus; hVISA, heteroresistant vancomycin-intermediate Staphylococcus aureus.
c
Isolates that were used in both standard- and high-inoculum studies.